Table 3.
Univariate and multivariate analysis of factors associated with multiple (≥2) site recurrence and early (≤6 months) recurrence after systemic therapy plus radiofrequency ablation of colorectal liver metastases.
| Variable | No. of patients |
Multiple site recurrence | Early recurrence | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||
| Multiple site recurrences n, (%) | p-value | OR (95% CI) |
p-value | Early recurrences n, (%) |
p-value | OR (95% CI) |
p-value | |||
| Patient and tumor characteristics | ||||||||||
| Age | 0.257 | 0.965 | ||||||||
| ≤ 60 years | 18 | 7 (38.9) | 9 (50) | |||||||
| > 60 years | 87 | 22 (25.3) | 43 (49.4) | |||||||
| Gender | 0.137 | 0.903 | ||||||||
| Male | 64 | 21 (32.8) | 32 (50) | |||||||
| Female | 41 | 8 (19.5) | 20 (48.8) | |||||||
| Primary tumor | 0.967 | 0.363 | ||||||||
| Colon | 83 | 23 (27.7) | 43 (51.8) | |||||||
| Rectum | 22 | 6 (27.3) | 9 (40.9) | |||||||
| Node status | 0.939 | 0.625 | ||||||||
| Positive | 73 | 20 (27.4) | 35 (47.9) | |||||||
| Negative | 32 | 9 (28.1) | 17 (53.1) | |||||||
| CLM | 0.215 | 0.038 | ||||||||
| Synchronous | 23 | 4 (17.4) | 7 (30.4) | |||||||
| Metachronous | 82 | 25 (30.5) | 45 (54.8) | |||||||
| CEA level before RFA | 0.453 | 0.002 | ||||||||
| ≤ 100 ng/ml | 64 | 16 (25.0) | 24 (37.5) | |||||||
| > 100 ng/ml | 41 | 13 (31.7) | 28 (68.3) | |||||||
| Maximum size of CLM | 0.009 | <0.001 | 4.91 (1.63-14.82) | 0.005 | ||||||
| ≤ 3 cm | 71 | 14 (19.7) | 26 (36.6) | |||||||
| 3-5 cm | 34 | 15 (44.1) | 26 (76.5) | |||||||
| Number of CLM | 0.003 | 3.47 (1.33-8.65) | 0.006 | 0.337 | ||||||
| 1-3 | 79 | 16 (20.2) | 37 (46.8) | |||||||
| 4-5 | 26 | 13 (50.0) | 15 (57.7) | |||||||
| Systemic therapy before RFA | ||||||||||
| Lines of therapy received | 0.346 | <0.001 | 3.33 (1.15-9.64) | 0.027 | ||||||
| 1 | 62 | 15 (24.2) | 20 (32.3) | |||||||
| ≥2 | 43 | 14 (32.6) | 32 (74.4) | |||||||
| Oxaliplatin used in last line | 0.745 | 0.488 | ||||||||
| Yes | 48 | 14 (29.2) | 22 (45.8) | |||||||
| No | 57 | 15 (26.3) | 30 (52.6) | |||||||
| Irinotecan used in last line | 0.579 | 0.058 | ||||||||
| Yes | 39 | 12 (30.8) | 24 (61.5) | |||||||
| No | 66 | 17 (25.7) | 28 (42.4) | |||||||
| Bevacizumab used in last line | 0.913 | 0.435 | ||||||||
| Yes | 21 | 6 (28.6) | 12 (57.1) | |||||||
| No | 84 | 23 (27.4) | 40 (47.6) | |||||||
| Cetuximab used in last line | 0.091 | 0.113 | ||||||||
| Yes | 7 | 0 (0 %) | 1 (14.3) | |||||||
| No | 98 | 29 (29.6) | 51 (52.0) | |||||||
| Response to last line regimen | 0.002 | 3.83 (1.48-10.85) | 0.001* | <0.001* | 6.34 (2.29-17.56) | <0.001 | ||||
| Partial remission | 55 | 9 (16.4) | 13 (23.6) | |||||||
| Stable disease | 21 | 6 (28.5) | 11 (52.4) | |||||||
| Progressive disease | 29 | 14 (48.3) | 28 (96.5) | |||||||
95% CI, 95% confidence interval; CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; OR, odds ratio; RFA, radiofrequency ablation.